These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 31589875)

  • 1. Effect of Aluminum Adjuvant and Preservatives on Structural Integrity and Physicochemical Stability Profiles of Three Recombinant Subunit Rotavirus Vaccine Antigens.
    Agarwal S; Hickey JM; McAdams D; White JA; Sitrin R; Khandke L; Cryz S; Joshi SB; Volkin DB
    J Pharm Sci; 2020 Jan; 109(1):476-487. PubMed ID: 31589875
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interaction of Aluminum-adjuvanted Recombinant P[4] Protein Antigen With Preservatives: Storage Stability and Backbone Flexibility Studies.
    Sawant N; Joshi SB; Weis DD; Volkin DB
    J Pharm Sci; 2022 Apr; 111(4):970-981. PubMed ID: 34758340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant Subunit Rotavirus Trivalent Vaccine Candidate: Physicochemical Comparisons and Stability Evaluations of Three Protein Antigens.
    Agarwal S; Hickey JM; Sahni N; Toth RT; Robertson GA; Sitrin R; Cryz S; Joshi SB; Volkin DB
    J Pharm Sci; 2020 Jan; 109(1):380-393. PubMed ID: 31400347
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterizing and Minimizing Aggregation and Particle Formation of Three Recombinant Fusion-Protein Bulk Antigens for Use in a Candidate Trivalent Rotavirus Vaccine.
    Agarwal S; Sahni N; Hickey JM; Robertson GA; Sitrin R; Cryz S; Joshi SB; Volkin DB
    J Pharm Sci; 2020 Jan; 109(1):394-406. PubMed ID: 31400346
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Formulation and preclinical studies with a trivalent rotavirus P2-VP8 subunit vaccine.
    Lakatos K; McAdams D; White JA; Chen D
    Hum Vaccin Immunother; 2020 Aug; 16(8):1957-1968. PubMed ID: 31995444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluating the Compatibility of New Recombinant Protein Antigens (Trivalent NRRV) with a Mock Pentavalent Combination Vaccine Containing Whole-Cell Pertussis: Analytical and Formulation Challenges.
    Kumar P; Holland DA; Secrist K; Taskar P; Dotson B; Saleh-Birdjandi S; Adewunmi Y; Doering J; Mantis NJ; Volkin DB; Joshi SB
    Vaccines (Basel); 2024 Jun; 12(6):. PubMed ID: 38932338
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapid Developability Assessments to Formulate Recombinant Protein Antigens as Stable, Low-Cost, Multi-Dose Vaccine Candidates: Case-Study With Non-Replicating Rotavirus (NRRV) Vaccine Antigens.
    Sawant N; Kaur K; Holland DA; Hickey JM; Agarwal S; Brady JR; Dalvie NC; Tracey MK; Velez-Suberbie ML; Morris SA; Jacob SI; Bracewell DG; Mukhopadhyay TK; Love KR; Love JC; Joshi SB; Volkin DB
    J Pharm Sci; 2021 Mar; 110(3):1042-1053. PubMed ID: 33285182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanism of Thimerosal-Induced Structural Destabilization of a Recombinant Rotavirus P[4] Protein Antigen Formulated as a Multi-Dose Vaccine.
    Kaur K; Xiong J; Sawant N; Agarwal S; Hickey JM; Holland DA; Mukhopadhyay TK; Brady JR; Dalvie NC; Tracey MK; Love KR; Love JC; Weis DD; Joshi SB; Volkin DB
    J Pharm Sci; 2021 Mar; 110(3):1054-1066. PubMed ID: 33278412
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantification of trivalent non-replicating rotavirus vaccine antigens in the presence of aluminum adjuvant.
    McAdams D; Lakatos K; Estrada M; Chen D; Plikaytis B; Sitrin R; White JA
    J Immunol Methods; 2021 Jul; 494():113056. PubMed ID: 33857473
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preformulation characterization of an aluminum salt-adjuvanted trivalent recombinant protein-based vaccine candidate against Streptococcus pneumoniae.
    Iyer V; Hu L; Liyanage MR; Esfandiary R; Reinisch C; Meinke A; Maisonneuve J; Volkin DB; Joshi SB; Middaugh CR
    J Pharm Sci; 2012 Sep; 101(9):3078-90. PubMed ID: 22538529
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analytical and Preformulation Characterization Studies of Human Papillomavirus Virus-Like Particles to Enable Quadrivalent Multi-Dose Vaccine Formulation Development.
    Jerajani K; Wan Y; Hickey JM; Kumru OS; Sharma N; Pullagurla SR; Ogun O; Mapari S; Whitaker N; Brendle S; Christensen ND; Batwal S; Mahedvi M; Rao H; Dogar V; Chandrasekharan R; Shaligram U; Joshi SB; Volkin DB
    J Pharm Sci; 2022 Nov; 111(11):2983-2997. PubMed ID: 35914546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tandem truncated rotavirus VP8* subunit protein with T cell epitope as non-replicating parenteral vaccine is highly immunogenic.
    Wen X; Cao D; Jones RW; Hoshino Y; Yuan L
    Hum Vaccin Immunother; 2015; 11(10):2483-9. PubMed ID: 26091081
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and immunogenicity of a parenterally administered rotavirus VP8 subunit vaccine in healthy adults.
    Fix AD; Harro C; McNeal M; Dally L; Flores J; Robertson G; Boslego JW; Cryz S
    Vaccine; 2015 Jul; 33(31):3766-72. PubMed ID: 26065919
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the compatibility of a second generation recombinant anthrax vaccine with aluminum-containing adjuvants.
    Jendrek S; Little SF; Hem S; Mitra G; Giardina S
    Vaccine; 2003 Jun; 21(21-22):3011-8. PubMed ID: 12798645
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of a quartz crystal microbalance platform to study protein adsorption on aluminum hydroxide vaccine adjuvants: Focus on phosphate-hydroxide ligand exchanges.
    Art JF; Soumillion P; Dupont-Gillain CC
    Int J Pharm; 2020 Jan; 573():118834. PubMed ID: 31715342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Formulation of botulinum neurotoxin heavy chain fragments for vaccine development: mechanisms of adsorption to an aluminum-containing adjuvant.
    DePaz RA; Henderson I; Advant SJ
    Vaccine; 2005 Jul; 23(31):4029-35. PubMed ID: 15963360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Physiochemical and functional characterization of antigen proteins eluted from aluminum hydroxide adjuvant.
    Hutcheon CJ; Becker JO; Russell BA; Bariola PA; Peterson GJ; Stroop SD
    Vaccine; 2006 Nov; 24(49-50):7214-25. PubMed ID: 16860908
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stabilization of a recombinant ricin toxin A subunit vaccine through lyophilization.
    Hassett KJ; Cousins MC; Rabia LA; Chadwick CM; O'Hara JM; Nandi P; Brey RN; Mantis NJ; Carpenter JF; Randolph TW
    Eur J Pharm Biopharm; 2013 Oct; 85(2):279-86. PubMed ID: 23583494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune response to antigen adsorbed to aluminum hydroxide particles: Effects of co-adsorption of ALF or ALFQ adjuvant to the aluminum-antigen complex.
    Beck Z; Torres OB; Matyas GR; Lanar DE; Alving CR
    J Control Release; 2018 Apr; 275():12-19. PubMed ID: 29432824
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NaCl strongly modifies the physicochemical properties of aluminum hydroxide vaccine adjuvants.
    Art JF; Vander Straeten A; Dupont-Gillain CC
    Int J Pharm; 2017 Jan; 517(1-2):226-233. PubMed ID: 27956190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.